05:57 AM EDT, 10/14/2024 (MT Newswires) -- GSK (GSK) said Monday that its phase 3 clinical trials ANCHOR-1 and ANCHOR-2 assessing the efficacy and safety of depemokimab versus placebo in adults with chronic rhinosinusitis with nasal polyps met their primary endpoints.

Depemokimab is an ultra-long-acting biologic administered once every six months, the company said.

Both trials observed a statistically significant reduction from baseline in total endoscopic nasal polyp score at 52 weeks and in mean nasal obstruction score from weeks 49 to 52.

Price: 38.79, Change: -0.04, Percent Change: -0.10